Cachexia


Article Author:
Janna Baker Rogers


Article Editor:
Jeffrey Minteer


Editors In Chief:
Evelyn Metz
Julie Sewell
Aditya Arya


Managing Editors:
Avais Raja
Orawan Chaigasame
Carrie Smith
Abdul Waheed
Khalid Alsayouri
Trevor Nezwek
Radia Jamil
Patrick Le
Anoosh Zafar Gondal
Saad Nazir
William Gossman
Hassam Zulfiqar
Steve Bhimji
John Shell
Matthew Varacallo
Heba Mahdy
Ahmad Malik
Sarosh Vaqar
Mark Pellegrini
James Hughes
Beata Beatty
Nazia Sadiq
Hajira Basit
Phillip Hynes
Tehmina Warsi


Updated:
2/14/2019 7:59:33 AM

Introduction

Cachexia is a complicated metabolic syndrome related to underlying illness and characterized by muscle mass loss with or without fat mass loss that is often associated with anorexia, an inflammatory process, insulin resistance, and increased protein turnover.[1][2][3][4][5]

Etiology

Cachexia causes weight loss and increased mortality. The major cause is cytokine excess. Other mediators include testosterone and insulin-like growth factor-I deficiency, excess myostatin, and excess glucocorticoids.

Epidemiology

In cancer patients, the overall prevalence of cachexia ranges from 40% at cancer diagnosis to 70% in advanced disease. In 20% to 25% of patients with advanced solid tumors, it is considered the primary cause of death in addition to being a significant comorbidity reducing median survival by up to 30%. Although less well delineated, cachexia is also associated with other chronic diseases including chronic obstructive pulmonary disease (COPD), chronic heart failure, chronic kidney disease, and chronic infectious and inflammatory diseases including AIDS. Significantly shorter survival in advanced cancer patients with cachexia has been identified relative to those without cachexia.[6][7][8][9]

Pathophysiology

Cachexia is characterized by a persistent increase in basal metabolic rate that is not compensated by increased caloric/protein intake. Factors involved in this abnormal metabolic cascade include digestive factors, tumor factors and hormonal responses to the primary disease. Digestive factors resulting in poor intake include dysgeusia, nausea, dysphagia, mucositis, and constipation. Tumor-mediated factors have been identified that activate proteolysis and lipolysis. Inflammatory mediators such as cytokines which include tumor necrosis factor and the interleukins induce anorexia while increasing glucagon, cortisol, and catecholamines producing a catabolic, hypermetabolic state.  Hormonal anabolic mediators such as growth hormone, insulin-like growth factor-1 (IGF-1), testosterone, and ghrelin are reduced. In heart failure, angiotensin-II causes muscle wasting likely through the ubiquitin-proteasome system, resulting in myocyte apoptosis and significant reduction of protein synthesis. Asthenia results in part from subsequent decreases in size and number of type 1 and type 2 muscle fibers and also reduced skeletal blood flow. 

History and Physical

History frequently includes a report of significant weight loss associated with the lack of appetite. Also, there is a reduction of quality of life associated with increased fatigue and poor tolerance to activity. In advanced cancer patients, cachexia is correlated with increased severity of multiple symptoms. These include lack of appetite, dry mouth, vomiting, dysgeusia, early satiety, and diarrhea. It also increases the severity of less intuitive symptoms such as pain, fatigue, and loss of energy, sleep disturbances, and anxiety. This excess symptom burden is independent of age, tumor stage, and treatment type. Diagnostic criteria for cachexia are a 5% weight loss in 12 months or a body mass index of less than 20 kg/m2 in the presence of a known chronic disease with at least 3 of the following factors: 

  • Loss of muscle mass, 
  • Asthenia
  • Loss of body fat, in the presence of inflammation as evidenced by albumen less than 3.2 g/dL or increased C–reactive protein.

The physical exam is nonspecific. Exam findings may be normal early in the course of the disease. Other findings might include bitemporal muscle wasting, supraclavicular wasting, and general lack of muscle definition.

Evaluation

Supporting laboratory evidence includes albumen less than 3.2 g/lL, a pre-albumin value of less than 10 mg/dL, a transferrin level less than 100 mg/dL, and an elevated C–reactive protein.

Treatment / Management

 [10]Disease stages have been described as pre-cachexia, cachexia, and refractory cachexia. Consensus definitions for these stages are as follows: 

  • Pre-cachexia, when weight loss more than 1kg but less than 5%
  • Cachexia, when weight loss is more than 5% or when weight loss is more than 2% with BMI less than 20kg/m
  • Refractory cachexia, when weight loss is more than 15% with body mass index (BMI) less than 23kg/m or when weight loss is more than 20% with BMI less than 27 kg/m

Although the prognostic usefulness of these definitions has not been established, it would appear that addressing cachexia at an earlier stage might ameliorate the destructive effects of the primary condition.[1][10][11]

A multimodal approach aimed at improving appetite, reducing the inflammatory response, improving outcomes and quality of life is the focus of ongoing research. Currently, no proven therapy accomplishes all of these goals. Most of the research has focused on improving appetite. Adequate nutrition remains an important aspect of this multimodal approach. However, increasing calorie–protein intake by definition does not reverse this abnormal metabolic state. Reversing the metabolic derangement through attenuation of tumor-related.

Factors and inflammatory mediators remain of central importance. Studies indicate that interleukin-6 has a primary role in initiating inflammatory cascade along with the contribution of tumor necrosis factor-alpha and other cytokines. Interventions that are used or that are under current investigation may be useful theoretically due to their effects on this inflammatory cascade, abnormal hormone responses, and/or the hypermetabolic derangements seen in cachexia.

Physical activity may attenuate the effects of cachexia by altering muscle metabolism through increased protein synthesis and reduced degradation pathways. In addition, exercise may increase insulin sensitivity, reduce oxidative stress, and reduce response to inflammation. Both aerobic exercise and resistance exercise have proven beneficial. Resistance exercise supplemented with branched-chain amino acids can reduce sarcopenia and cachexia.

The most studied and effective treatment for anorexia has been megestrol acetate and a dose of 320 mg to 800 mg per day. The literature supports that 30% of patients demonstrate an increased appetite associated with an increased body mass index primarily through increased fat and some associated improvement in the quality of life. However, no study has demonstrated improved survival. Side effects include adrenal suppression and increase the incidence of DVT in a minority of patients. Corticosteroid has been shown to have a positive effect on appetite but, due to side effect profile, is only indicated for short-term (less than 4 weeks) treatment. In addition to appetite stimulation, steroids theoretically may reduce the inflammatory state.

Other medications that require additional confirmation includes cannabinoids (only effective in AIDS so far), non-steroidal anti-inflammatory drugs, and omega-3 fatty acids. Existing evidence suggests it is reasonable to initiate a trial of omega-3 fatty acids in patients with life expectancies longer than 8 weeks. Other medications including Ghrelin, beta-2 agonists, selective androgen receptor modulators, aliskiren, resveratrol, leucine, and thalidomide are all under active investigation with some positive early trends.

In patients with cardiac cachexia, treatment with the beta-blocker carvedilol has demonstrated meaningful reversal of cachexia. This may be in part due to improvement in the hypermetabolic state seen in cachexia. Pre-clinical studies suggest that ACE-inhibitors and angiotensin II receptor blockers have muscle-protective properties related to mitochondrial function, insulin sensitivity, and local inflammation.

Pearls and Other Issues

Cachexia is a syndrome of altered metabolic activity resulting in muscle protein loss that is present in up to two-thirds of patients with advanced cancer. It is estimated that 20% of patients with solid cancers die directly as a result of cachexia. Also, survival decreases to 30% in patients with this associated major comorbidity. This syndrome remains poorly recognized, treated and prevented. The current appetite stimulants have been effective in increasing weight 30% of patients, but improved survival in patients with cachexia has not been demonstrated. Clinical research directed at reducing the inflammatory state and tumor-related factors have shown some promise.

Enhancing Healthcare Team Outcomes

A multimodal approach aimed at improving appetite, reducing the inflammatory response, improving outcomes and quality of life is the focus of ongoing research. The management of cachexia requires a multidisciplinary team that includes an oncologist, gastroenterologist, dietitian, primary provider, nurse practitioner and a surgeon. Currently, no proven therapy accomplishes all of these goals. Most of the research has focused on improving appetite. Adequate nutrition remains an important aspect of this multimodal approach. However, increasing calorie–protein intake by definition does not reverse this abnormal metabolic state. Reversing the metabolic derangement through attenuation of tumor-related.

Physical activity may attenuate the effects of cachexia by altering muscle metabolism through increased protein synthesis and reduced degradation pathways. In addition, exercise may increase insulin sensitivity, reduce oxidative stress, and reduce response to inflammation. Both aerobic exercise and resistance exercise have proven beneficial. Resistance exercise supplemented with branched-chain amino acids can reduce sarcopenia and cachexia.

Even though a number of drugs have been used to manage cachexia, none works reliably or consistently. The outcomes for most patients depends on the cause. Those with malignancy tend to have the worst outcomes.[12][13] (Level V)

 


Interested in Participating?

We are looking for contributors to author, edit, and peer review our vast library of review articles and multiple choice questions. In as little as 2-3 hours you can make a significant contribution to your specialty. In return for a small amount of your time, you will receive free access to all content and you will be published as an author or editor in eBooks, apps, online CME/CE activities, and an online Learning Management System for students, teachers, and program directors that allows access to review materials in over 500 specialties.

Improve Content - Become an Author or Editor

This is an academic project designed to provide inexpensive peer-reviewed Apps, eBooks, and very soon an online CME/CE system to help students identify weaknesses and improve knowledge. We would like you to consider being an author or editor. Please click here to learn more. Thank you for you for your interest, the StatPearls Publishing Editorial Team.

Cachexia - Questions

Take a quiz of the questions on this article.

Take Quiz
A 73-year-old male has had metastatic prostate cancer for 9 months and has lost 13 kg. He has had some anorexia but is still eating. Select the mediator that may be causing the weight loss.



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up
Which of the following is false regarding cachexia?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up
Which of the following medications has not been shown to improve appetite in some patients with cachexia?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up
The following medications have been shown to improve appetite in some patients with cachexia except:



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up
Which of the following statements is true regarding sarcopenia seen in patients with cachexia?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up

Cachexia - References

References

Wang J,Wang Y,Tong M,Pan H,Li D, New Prospect for Cancer Cachexia: Medical Cannabinoid. Journal of Cancer. 2019;     [PubMed]
Reid J,McKeaveney C,Martin P, Communicating with Adolescents and Young Adults about Cancer-Associated Weight Loss. Current oncology reports. 2019 Feb 4;     [PubMed]
Resmark G,Herpertz S,Herpertz-Dahlmann B,Zeeck A, Treatment of Anorexia Nervosa-New Evidence-Based Guidelines. Journal of clinical medicine. 2019 Jan 29;     [PubMed]
Rasche T,Emmert D,Stieber C,Conrad R,Mücke M, [Cannabis and cannabinoids-easier access, hype and disappointment : What has been confirmed in therapy?] Der Internist. 2019 Jan 24;     [PubMed]
Fairman CM,Kendall KL,Hart NH,Taaffe DR,Galvão DA,Newton RU, The potential therapeutic effects of creatine supplementation on body composition and muscle function in cancer. Critical reviews in oncology/hematology. 2019 Jan;     [PubMed]
Yakovenko A,Cameron M,Trevino JG, Molecular therapeutic strategies targeting pancreatic cancer induced cachexia. World journal of gastrointestinal surgery. 2018 Dec 27;     [PubMed]
Park B,You S,Cho WCS,Choi JY,Lee MS, A systematic review of herbal medicines for the treatment of cancer cachexia in animal models. Journal of Zhejiang University. Science. B. 2019 Jan.;     [PubMed]
Hendifar AE,Petzel MQB,Zimmers TA,Denlinger CS,Matrisian LM,Picozzi VJ,Rahib L, Pancreas Cancer-Associated Weight Loss. The oncologist. 2018 Dec 27;     [PubMed]
Suzuki T,Palus S,Springer J, Skeletal muscle wasting in chronic heart failure. ESC heart failure. 2018 Dec;     [PubMed]
O'Reilly D,Fou L,Hasler E,Hawkins J,O'Connell S,Pelone F,Callaway M,Campbell F,Capel M,Charnley R,Corrie P,Elliot D,Goodburn L,Jewell A,Joharchi S,McGeeney L,Mukherjee S,Oppong K,Whelan P,Primrose J,Neoptolemos J, Diagnosis and management of pancreatic cancer in adults: A summary of guidelines from the UK National Institute for Health and Care Excellence. Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]. 2018 Dec;     [PubMed]
Kaduka LU,Bukania ZN,Opanga Y,Mutisya R,Korir A,Thuita V,Nyongesa C,Mwangi M,Mbakaya CFL,Muniu E, Malnutrition and cachexia among cancer out-patients in Nairobi, Kenya. Journal of nutritional science. 2017;     [PubMed]
Opsomer S,Joossens S,De Wit C,Lauwerier E,Pype P, Couples coping with nutrition-related problems in advanced cancer: A qualitative study in primary care. European journal of oncology nursing : the official journal of European Oncology Nursing Society. 2019 Feb;     [PubMed]
Crawford J, What are the criteria for response to cachexia treatment? Annals of palliative medicine. 2019 Jan;     [PubMed]

Disclaimer

The intent of StatPearls is to provide practice questions and explanations to assist you in identifying and resolving knowledge deficits. These questions and explanations are not intended to be a source of the knowledge base of all of medicine, nor is it intended to be a board or certification review of NP-Gerontology Primary Care. The authors or editors do not warrant the information is complete or accurate. The reader is encouraged to verify each answer and explanation in several references. All drug indications and dosages should be verified before administration.

StatPearls offers the most comprehensive database of free multiple-choice questions with explanations and short review chapters ever developed. This system helps physicians, medical students, dentists, nurses, pharmacists, and allied health professionals identify education deficits and learn new concepts. StatPearls is not a board or certification review system for NP-Gerontology Primary Care, it is a learning system that you can use to help improve your knowledge base of medicine for life-long learning. StatPearls will help you identify your weaknesses so that when you are ready to study for a board or certification exam in NP-Gerontology Primary Care, you will already be prepared.

Our content is updated continuously through a multi-step peer review process that will help you be prepared and review for a thorough knowledge of NP-Gerontology Primary Care. When it is time for the NP-Gerontology Primary Care board and certification exam, you will already be ready. Besides online study quizzes, we also publish our peer-reviewed content in eBooks and mobile Apps. We also offer inexpensive CME/CE, so our content can be used to attain education credits while you study NP-Gerontology Primary Care.